Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis.

Humans Bevacizumab Vascular Endothelial Growth Factor A / metabolism Polylactic Acid-Polyglycolic Acid Copolymer / chemistry Neovascularization, Pathologic / drug therapy Human Umbilical Vein Endothelial Cells Collagen Printing, Three-Dimensional
3D printing Anti-angiogenic effect Cartilage PLGA Protein delivery meniscus

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
08 2023
Historique:
received: 17 02 2023
revised: 05 06 2023
accepted: 08 07 2023
medline: 21 8 2023
pubmed: 15 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

Pathological angiogenesis is a crucial attribute of several chronic diseases such as cancer, age-related macular degeneration, and osteoarthritis (OA). In the case of OA, pathological angiogenesis mediated by the vascular endothelial growth factor (VEGF), among other factors, contributes to cartilage degeneration and to implants rejection. In line with this, the use of the anti-VEGF bevacizumab (BVZ) has been shown to prevent OA progression and support cartilage regeneration. The aim of this work was to functionalize a medical grade collagen with poly (lactic-co-glycolic acid) (PLGA) microparticles containing BVZ via three-dimensional (3D) printing to target pathological angiogenesis. First, the effect of several formulation parameters on the encapsulation and release of BVZ from PLGA microparticles was studied. Then, the anti-angiogenic activity of released BVZ was tested in a 3D cell model. The 3D printability of the microparticle-loaded collagen ink was tested by evaluating the shape fidelity of 3D printed structures. Results showed that the release and the encapsulation efficiency of BVZ could be tuned as a function of several formulation parameters. In addition, the released BVZ was observed to reduce vascularization by human umbilical vein endothelial cells. Finally, the collagen ink with embedded BVZ microparticles was successfully printed, leading to shape-stable meniscus-, nose- and auricle-like structures. Taken altogether, we defined the conditions for the successful combination of BVZ-loaded microparticles with the 3D printing of a medical grade collagen to target pathological angiogenesis.

Identifiants

DOI: 10.1016/j.jconrel.2023.07.017 PMID: 37451546
pubmed: 37451546
pii: S0168-3659(23)00444-3
doi: 10.1016/j.jconrel.2023.07.017
pii:
doi:

Substances chimiques

Bevacizumab 2S9ZZM9Q9V
Vascular Endothelial Growth Factor A 0
Polylactic Acid-Polyglycolic Acid Copolymer 1SIA8062RS
Collagen 9007-34-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

747-758

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing interest Niklaus Stiefel and Carla Zihlmann are employees of Geistlich Pharma AG. Geistlich Pharma AG provided the collagen material used in this study. Geistlich Pharma AG manufactures and commercializes collagen-based products for tissue regeneration. The other authors do not have any conflict of interests.

Auteurs

Anna Abbadessa (A)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), IDIS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: anna.abbadessa@usc.es.

Paulina Nuñez Bernal (P)

Department of Orthopaedics, University Medical Center Utrecht, Utrecht, the Netherlands. Electronic address: P.NunezBernal@umcutrecht.nl.

Giorgio Buttitta (G)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), IDIS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: giorgio.buttitta@rai.usc.es.

Alfredo Ronca (A)

Institute of Polymers, Composites and Biomaterials, National Research Council (IPCB-CNR), Naples, Italy. Electronic address: alfredo.ronca@cnr.it.

Ugo D'Amora (U)

Institute of Polymers, Composites and Biomaterials, National Research Council (IPCB-CNR), Naples, Italy. Electronic address: ugo.damora@cnr.it.

Carla Zihlmann (C)

Geistlich Pharma AG, Wolhusen, Switzerland. Electronic address: carla.zihlmann@geistlich.com.

Niklaus Stiefel (N)

Geistlich Pharma AG, Wolhusen, Switzerland. Electronic address: Niklaus.Stiefel@geistlich.com.

Luigi Ambrosio (L)

Institute of Polymers, Composites and Biomaterials, National Research Council (IPCB-CNR), Naples, Italy. Electronic address: luigi.ambrosio@cnr.it.

Jos Malda (J)

Department of Orthopaedics, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands. Electronic address: J.Malda@umcutrecht.nl.

Riccardo Levato (R)

Department of Orthopaedics, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands. Electronic address: R.Levato-2@umcutrecht.nl.

José Crecente-Campo (J)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), IDIS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: jose.crecente@usc.es.

María José Alonso (MJ)

Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), IDIS Research Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. Electronic address: mariaj.alonso@usc.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Biofunctionalization of 3D printed collagen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Bévacizumab › Biofunctionalization of 3D printed collagen...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Protéines angiogéniques › Facteurs de croissance endothéliale vasculaire › Facteur de croissance endothéliale vasculaire de type A › Biofunctionalization of 3D printed collagen...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyesters › Acide polyglycolique › Copolymère d'acide poly(lactique-co-glycolique) › Biofunctionalization of 3D printed collagen...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Métaplasie › Néovascularisation pathologique › Biofunctionalization of 3D printed collagen...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules endothéliales › Cellules endothéliales de la veine ombilicale humaine › Biofunctionalization of 3D printed collagen...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Scléroprotéines › Protéines de la matrice extracellulaire › Collagène › Biofunctionalization of 3D printed collagen...
questionsmedicales.fr › Sciences de l'information › Affichage de données › Infographie › Conception assistée par ordinateur › Impression tridimensionnelle › Biofunctionalization of 3D printed collagen...